# AltheaDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/altheadx

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.altheadx.com
- Total disclosed funding: $36M
- Latest round: Series C (Dec 14, 2015)
- Investors on record: 5

## About

AltheaDx Inc. is a biotechnology company focused on developing advanced diagnostic tests to enhance patient care in oncology, particularly in the management of skin cancers such as melanoma and squamous cell carcinoma.Founded in 2013, AltheaDx Inc. is based in San Diego, US, and specializes in diagnostic solutions for skin cancers. The company was acquired by Castle Biosciences Incorporated in a transaction valued at USD 65 mn, completed on April 26, 2022. The founders include François Ferré and Magda Marquet, and the current CEO is David Nikodem. AltheaDx has participated in 11 investment deals, raising a total of USD 3.73 mn, with its most recent funding round being an Add-on Trade Sale led by Castle Biosciences Incorporated.AltheaDx Inc. offers a range of advanced diagnostic tests aimed at improving the management and treatment of skin cancers, including the DecisionDx-Melanoma and DecisionDx-SCC tests, which assess the metastatic risk and predict recurrence in melanoma and squamous cell carcinoma patients, respectively. It also provides TissueCypher for Barrett's Esophagus and MyPath Melanoma, enhancing diagnostic accuracy for these conditions. Their products are marketed primarily in the United States, with plans for international expansion.In the most recent fiscal year, AltheaDx reported a revenue of USD 7.35 mn and an EBITDA of USD -3.58 mn. The company’s revenue model is based on transactional billing for its diagnostic tests, facilitated through partnerships with healthcare providers and insurance reimbursements.Looking forward, AltheaDx plans to leverage its recent acquisition to enhance its product offerings and expand into new global markets. With the support of the USD 65 mn funding from Castle Biosciences, the company aims to innovate and launch new diagnostic tests tailored for oncology. AltheaDx is targeting rapid growth in international markets, particularly in Europe and Asia, by the end of 2023, capitalizing on the increasing demand for personalized medicine in oncology.

## Funding rounds

- Series C, Dec 14, 2015, $30M — Ally Bridge Group, 6 Dimensions Capital, ALMA Life Sciences, Wuxi AppTec Group
- Series A, Mar 10, 2010, $6M — Telegraph Hill Partners

## Investors

- Telegraph Hill Partners (https://capitalatlas.ai/funds/telegraph-hill-partners) — Series A
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series C
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series C
- ALMA Life Sciences (https://capitalatlas.ai/funds/alma-life-sciences) — Series C
- Wuxi AppTec Group — Series C